Participants and Location:
This study will recruit up to 10 patients of at least 18 years of age with ascites due to diagnosed ovarian cancer. Eligible study patients will be screened and recruited at BC Cancer - Victoria. Paracentesis procedure and patient consent will occur at the Island Health - Royal Jubilee Hospital.
Study Design:
Participants meeting the inclusion criteria will be fitted with a continuous glucose monitor (FreeStyle Libre) before proceeding to their scheduled appointment for paracentesis. Labeled glucose will be administered via I.V. at dose of 8g of labeled glucose in 60 mL over 10 min. This is followed by 4g of labeled glucose in 30 mL over an hour.
Sample collection and processing:
During \[U-13C\]glucose infusions, the ascites specimens will kept on ice. Samples will be collected and analyzed by flow cytometry and mass spectrometry for states of metabolism and metabolite profiles respectively. The ascites fluid will be monitored for changes in metabolite levels.
\[U-13C\]glucose Product Information:
\[U-13C\]glucose clinical grade will be compound BC Cancer Pharmacy.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Ovarian cancer
Any stage or grade of disease
Ascites fluid that requires draining
Any treatment regimen
Primary or recurrent ascites
Understands the concept of the study and give informed consent.
You may not be if
Participants must not have diabetes or abnormal hemoglobin A1C levels.
The patient's glucose levels must be between 4 - 11.1 mM before administering an infusion. This is to ensure that patients are within normal blood glucose levels, as described by Diabetes Canada.
Participants cannot receive chemotherapy treatment during the 5 hour duration of the experiment as it may compromise the integrity of the data.
Clareo Health | 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
